Valuation: VentriPoint Diagnostics Ltd.

Market Cap 20.06M 14.31M 12.39M 11.55M 10.62M 1.36B 20.28M 136M 53.28M 681M 53.74M 52.55M 2.25B P/E 2024
-3.22x
P/E 2025 -7.24x
Enterprise Value 22.61M 16.13M 13.97M 13.02M 11.98M 1.53B 22.87M 153M 60.07M 767M 60.58M 59.25M 2.54B EV / Sales 2024
187x
EV / Sales 2025 145x
Free-Float
98.51%
Yield 2024 *
-
Yield 2025 -
07-29 Ventripoint Diagnostics Ltd. Announces the Appointment of Philip M. Toleikis to its Board of Directors CI
07-20 Ventripoint Diagnostics Selects VMS+ Technology For Use In AIRES Clinical Research Study CI
06-15 Ventripoint Diagnostics Ltd. and Global Congenital Heart Disease Alliance Announce Support for Global Congenital Heart Disease Alliance CI
05-27 Ventripoint Diagnostics Ltd. - Shareholder/Analyst Call
05-21 Ventripoint Diagnostics Ltd. announced that it has received CAD 0.30803 million in funding CI
05-01 Ventripoint Diagnostics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-30 Ventripoint Diagnostics Ltd. Auditor Raises 'Going Concern' Doubt CI
04-28 Ventripoint Diagnostics Ltd. Announces Its Strategic Partner, Lishman Global Inc. Formally Submits Ventripoint's VMS+TM 4.0 System to China's National Medical Products Administration CI
04-01 Ventripoint Diagnostics Ltd. and Health Division of the Montecristo Group Announce Collaboration to Explore Expanded Cardiac Screening, Clinical Research, and AI-Assisted Echocardiography in Costa Rica CI
03-17 Ventripoint Diagnostics Ltd And First Light Health Partner To Bring AI-Powered Cardiac Diagnostics To Indigenous And Remote Communities CI
03-03 Ventripoint Diagnostics Ltd. And LG Consulting Solutions Sign Commercial Agreement For VMS+ Deployment In Northern California CI
02-26 Ventripoint Diagnostics Ltd. - Shareholder/Analyst Call
01-19 Ventripoint Diagnostics Ltd. announced that it has received CAD 1.009772 million in funding CI

Last Transcript: VentriPoint Diagnostics Ltd.

Manager TitleAgeSince
Chief Executive Officer - 2024-02-04
Director of Finance/CFO - 2025-12-02
Chief Executive Officer 78 2010-09-30
Director TitleAgeSince
Chairman 78 2019-12-16
Director/Board Member - 2021-10-24
Director/Board Member - 2021-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.03% - - 14.31M
+2.32%+0.24%+23.89%+5.32% 214B
+2.51%+1.61%+0.31%-21.63% 140B
+1.88%+6.26%-21.34%+21.30% 133B
-2.75%+3.69%-54.46%-5.88% 69.19B
-0.70%+3.74%+12.28%+11.84% 51.28B
+0.62%+4.53%-14.27%-20.39% 50.43B
+1.37%+0.58%+22.82%+11.73% 39.85B
+0.99%+5.41%+42.25%+37.98% 39.27B
+0.40%+4.55%-21.39%+24.98% 32.32B
Average +0.45%+3.77%-1.10%+7.25% 85.43B
Weighted average by Cap. +0.95%+3.04%+0.44%+3.72%

Financials

2024 2025
Net sales 95.17K 67.89K 58.8K 54.81K 50.41K 6.46M 96.24K 644K 253K 3.23M 255K 249K 10.7M 180K 128K 111K 104K 95.31K 12.2M 182K 1.22M 478K 6.11M 482K 471K 20.22M
Net income -4.92M -3.51M -3.04M -2.83M -2.61M -334M -4.97M -33.29M -13.07M -167M -13.18M -12.89M -553M -3.2M -2.28M -1.98M -1.84M -1.7M -217M -3.24M -21.66M -8.5M -109M -8.57M -8.39M -360M
Net Debt 1.57M 1.12M 973K 907K 834K 107M 1.59M 10.65M 4.18M 53.43M 4.22M 4.12M 177M 2.56M 1.82M 1.58M 1.47M 1.35M 173M 2.58M 17.3M 6.79M 86.75M 6.85M 6.7M 287M
Logo VentriPoint Diagnostics Ltd.
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
Employees
-